What is BofA Securities's price target for DNA?

BofA Securities's latest stated price target for Ginkgo Bioworks Holdings Inc. (DNA) is $3, from its action on May 18, 2022.

What is BofA Securities's rating on DNA?

BofA Securities rates DNA Underperform, a bearish rating, as of May 18, 2022.

When did BofA Securities last change its view on DNA?

On May 18, 2022, BofA Securities downgrades to Underperform from Neutral, price target $3.

Analyst firms · BofA Securities · DNA

BofA Securities DNA price target and rating history

Ginkgo Bioworks Holdings Inc. (DNA) · Health Care

BofA Securities rates Ginkgo Bioworks Holdings Inc. (DNA) Underperform with a $3 price target, as of its latest action on May 18, 2022. It has published 3 rating actions on DNA since January 2022, including 0 upgrades and 1 downgrade.

Current rating: Underperform
Price target: $3
Median target, all firms: Too few
Actions on DNA: 3

BofA Securities price target on DNA

BofA Securities price target on DNA, each point a stated target, January 2022 to May 2022.

Every BofA Securities rating on DNA

May 18, 2022
DowngradeBofA Securities downgrades to Underperform from Neutral, price target $3
Feb 1, 2022
InitiateBofA Securities starts coverage at Neutral, price target $6
Jan 28, 2022
InitiateBofA Securities starts coverage at Buy, price target $8

Questions about BofA Securities and DNA

What is BofA Securities's price target for DNA?: BofA Securities's latest stated price target for Ginkgo Bioworks Holdings Inc. (DNA) is $3, from its action on May 18, 2022.
What is BofA Securities's rating on DNA?: BofA Securities rates DNA Underperform, a bearish rating, as of May 18, 2022.
When did BofA Securities last change its view on DNA?: On May 18, 2022, BofA Securities downgrades to Underperform from Neutral, price target $3.

More DNA rating histories

All BofA Securities ratings DNA news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.